Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
788 USD | +1.26% | +2.70% | +35.70% |
Financials (USD)
Sales 2024 * | 41.32B | Sales 2025 * | 51.34B | Capitalization | 701B |
---|---|---|---|---|---|
Net income 2024 * | 10.89B | Net income 2025 * | 15.74B | EV / Sales 2024 * | 17.3 x |
Net Debt 2024 * | 14.38B | Net Debt 2025 * | 7.93B | EV / Sales 2025 * | 13.8 x |
P/E ratio 2024 * |
64.3
x | P/E ratio 2025 * |
43.6
x | Employees | 43,000 |
Yield 2024 * |
0.67% | Yield 2025 * |
0.77% | Free-Float | 99.79% |
Latest transcript on Eli Lilly and Company
1 day | +1.56% | ||
1 week | +2.17% | ||
Current month | +4.42% | ||
1 month | +3.87% | ||
3 months | +35.48% | ||
6 months | +44.54% | ||
Current year | +35.00% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 59 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 18 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 791.1 | +1.67% | 1 113 026 |
24-03-27 | 778.2 | +0.42% | 2,297,713 |
24-03-26 | 774.9 | +0.23% | 2,099,042 |
24-03-25 | 773.1 | +0.33% | 1,806,584 |
24-03-22 | 770.6 | +0.05% | 1,981,019 |
Delayed Quote Nyse, March 28, 2024 at 10:54 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.00% | 701B | |
+26.24% | 571B | |
+1.28% | 381B | |
+20.70% | 334B | |
+16.77% | 319B | |
+1.12% | 210B | |
+2.47% | 210B | |
-6.18% | 201B | |
-3.18% | 157B | |
-0.68% | 153B |